Menu
Recruiting NCT07577570

Calcium Replacement Therapy in Postoperative Hypoparathyroidism

No phase Interventional Post-Thyroidectomy Hypoparathyroidism Treatment

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Calcium carbonate 1250 mg (500 mg elemental calcium) twice a day, Calcium carbonate 1250 mg (500 mg elemental calcium) 4 times a day.
Who it may be relevant to
Registry conditions: Post-Thyroidectomy Hypoparathyroidism Treatment. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Estonia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Pilot Study of Calcium Replacement Therapy in Postoperative Hypoparathyroidism

Overview

The goal of this clinical trial is to evaluate whether a lower-dose calcium replacement therapy is non-inferior to a higher-dose regimen in preventing symptomatic hypoparathyroidism in patients following thyroidectomy. The hypothesis is: • lower-dose calcium replacement therapy is non-inferior to higher-dose therapy in preventing symptomatic hypoparathyroidism during the first two postoperative weeks Researchers will compare patients receiving a lower-dose calcium replacement regimen with those receiving a higher-dose regimen to assess whether the lower dose is not associated with a higher incidence of symptomatic hypoparathyroidism. Patients who develop post-thyroidectomy hypoparathyroidism are divided into groups for calcium replacement therapy. If they are asymptomatic, they will be scheduled for a follow-up visit at two weeks after surgery. During the follow-up visit, calcium metabolism will be evaluated, and treatment adjusted if necessary.

Interventions

  • Drug Calcium carbonate 1250 mg (500 mg elemental calcium) twice a day
    One study group takes calcium carbonate 1250 mg (500 mg elemental calcium) twice a day (at lunchtime and in the evening)
  • Drug Calcium carbonate 1250 mg (500 mg elemental calcium) 4 times a day
    The second study group takes 1250 mg of calcium carbonate (500 mg of elemental calcium) four times a day (starting at noon, at approximately 4-hour intervals: at noon, in the early afternoon, in the evening, and before bedtime). This dosage regimen is prescribed because 500 mg of calcium can be absorbed at a time.

Primary outcome measures

  • Occurence of symptomatic hypoparathyroidism [Time frame: 2 weeks]
Secondary outcome measures (3)
  • Serum calcium levels at 2 week follow-up [Time frame: 2 weeks]
  • Duration and permanence of hypoparathyroidism [Time frame: Up to 12 months postoperatively]
  • Serum parathyroid hormone (PTH) levels at 2 week follow-up [Time frame: 2 weeks]

Eligibility criteria

Inclusion criteria

  • patients over the age of 18 undergoing surgery involving both lobes of the thyroid gland (thyroidectomy, "near-total" thyroidectomy, subtotal thyroidectomy, and "completed" thyroidectomy)
  • Based on the first post-operative day analysis, PTH levels are below the normal range (in our hospitals 1.8-7.8 pmol/l), but not so low (below 1.06 pmol/L) as to require calcium replacement therapy with calcitriol (rocaltrol)

Exclusion criteria

  • previously diagnosed osteoporosis; the patient is already taking calcium and vitamin D supplements prior to thyroid surgery
  • renal insufficiency (eGFR < 30)
  • patients with concomitant hyperparathyroidism undergoing simultaneous thyroidectomy and parathyroidectomy for a parathyroid adenoma

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Estonia · 2 centers
  • East Tallinn Central Hospital — Tallinn
  • Tartu University Hospital — Tartu

Identifiers

NCT: NCT07577570 · TartuUH-ETCH_403/T-13_2

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗